A pregnenolone derivative compound chosen among: - a compound of formula or a pharmaceutically acceptable salt thereof, wherein --- R1 denotes that C3 is substituted with -OH or =O, with C1-8 alkyl -R2 denotes that C17 is substituted with C1-8 alkyl, halogen or Bn-, --- R3 denotes that C20 is substituted with -OH or =O, and --- R4 denotes that C16 is substituted with -H, - a compound of formula: or a pharmaceutically acceptable salt thereof, wherein --- R1 denotes that C3 is substituted with -NH 2, Bn-O- or -N3, -R2 denotes that C17 is substituted with -H, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H or --- R1 denotes that C3 is substituted with C1-8 alkoxy, halogen, Bn-O- or -N 3, -R2 denotes that C17 is substituted with -Bn, -CH 3 or C2-6 alkenyl, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H, or --- R1 denotes that C3 is substituted with -OH, -R2 denotes that C17 is substituted with C1-8 alkyl, C1-8 alkoxy or Bn-, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H, or --- R1 denotes that C3 is substituted with -OH, -R2 denotes that C17 is substituted with -H, --- R3 denotes that C20 is substituted with -H, -OH or -NR8R9 wherein R8 and R9 each independently is H or C1-8 alkyl, and --- R4 denotes that C16 is substituted with -H, or - a compound of formula: or a pharmaceutically acceptable salt thereof, wherein: --- R1 denotes that C3 is substituted with -H, --- R3 denotes that C20 is substituted with -H, -OH or =O, and --- R4 denotes that C 16 is substituted with -H, - provided that in formulas B, D, and E when the bond between C3 and R1 is single, R1 is in β position, for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; and skin inflammatory and fibrotic diseases. - a compound of formula or a pharmaceutically acceptable salt thereof, wherein --- R1 denotes that C3 is substituted with -OH or =O, with C1-8 alkyl -R2 denotes that C17 is substituted with C1-8 alkyl, halogen or Bn-, --- R3 denotes that C20 is substituted with -OH or =O, and --- R4 denotes that C16 is substituted with -H, --- R1 denotes that C3 is substituted with -OH or =O, with C1-8 alkyl -R2 denotes that C17 is substituted with C1-8 alkyl, halogen or Bn-, --- R3 denotes that C20 is substituted with -OH or =O, and --- R4 denotes that C16 is substituted with -H, - a compound of formula: or a pharmaceutically acceptable salt thereof, wherein --- R1 denotes that C3 is substituted with -NH 2, Bn-O- or -N3, -R2 denotes that C17 is substituted with -H, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H or --- R1 denotes that C3 is substituted with C1-8 alkoxy, halogen, Bn-O- or -N 3, -R2 denotes that C17 is substituted with -Bn, -CH 3 or C2-6 alkenyl, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H, or --- R1 denotes that C3 is substituted with -OH, -R2 denotes that C17 is substituted with C1-8 alkyl, C1-8 alkoxy or Bn-, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H, or --- R1 denotes that C3 is substituted with -OH, -R2 denotes that C17 is substituted with -H, --- R3 denotes that C20 is substituted with -H, -OH or -NR8R9 wherein R8 and R9 each independently is H or C1-8 alkyl, and --- R4 denotes that C16 is substituted with -H, or --- R1 denotes that C3 is substituted with -NH 2, Bn-O- or -N3, -R2 denotes that C17 is substituted with -H, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H --- R1 denotes that C3 is substituted with C1-8 alkoxy, halogen, Bn-O- or -N 3, -R2 denotes that C17 is substituted with -Bn, -CH 3 or C2-6 alkenyl, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H, --- R1 denotes that C3 is substituted with -OH, -R2 denotes that C17 is substituted with C1-8 alkyl, C1-8 alkoxy or Bn-, --- R3 denotes that C20 is substituted with =O, and --- R4 denotes that C16 is substituted with -H, --- R1 denotes that C3 is substituted with -OH, -R2 denotes that C17 is substituted with -H, --- R3 denotes that C20 is substituted with -H, -OH or -NR8R9 wherein R8 and R9 each independently is H or C1-8 alkyl, and --- R4 denotes that C16 is substituted with -H, - a compound of formula: or a pharmaceutically acceptable salt thereof, wherein: --- R1 denotes that C3 is substituted with -H, --- R3 denotes that C20 is substituted with -H, -OH or =O, and --- R4 denotes that C 16 is substituted with -H, - provided that in formulas B, D, and E when the bond between C3 and R1 is single, R1 is in β position, --- R1 denotes that C3 is substituted with -H, --- R3 denotes that C20 is substituted with -H, -OH or =O, and --- R4 denotes that C 16 is substituted with -H, - provided that in formulas B, D, and E when the bond between C3 and R1 is single, R1 is in β position, - provided that in formulas B, D, and E when the bond between C3 and R1 is single, R1 is in β position,